1-1314-38

e1.Ethical considerations for neurologists in the management of chronic pain. Neurology 2001;57:2166–2167.

e2.Hill CS, Jr. Government regulatory influences on opioid prescribing and their impact on the treatment of pain of nonmalignant origin. J Pain Symptom Manage 1996;11:287–298.

e3.Washington Administrative Code (WAC) 246-919-830, 12/1999; Repealed 1/2012.

e4.Fauber J. UW a force in pain drug growth. Research group receiving millions from pharmaceutical firms helped liberalize use of opioids. Milwaukee Journal Sentinel. April 2, 2011 [online]. Available at: Accessed August 19, 2013.

e5.Meier B. Senate inquiry into painkiller makers' ties. New York Times, May 8, 2012. [online]. Available at: Accessed August 19, 2013.

e6.Saper JR, Lake AE, Bain PA, et al. A practice guide for continuous opioid therapy for refractory daily headache: patient selection, physician requirements, and treatment monitoring. Headache: The Journal of Head and Face Pain 2010;50:1175–1193.

e7.Eriksen J, Sjogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006;125:172–179.

e8.Turner JA, Hollingworth W, Comstock BA, Deyo RA. Spinal cord stimulation for failed back surgery syndrome: outcomes in a workers' compensation setting. Pain 2010;148:14–25.

e9.Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain 2009;25:170–175.

e10.Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004;11:354–365.

e11.Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Gen Intern Med 2010;25:310–315.

e12.Creanga AA, Sabel JC, Ko JY, et al. Maternal drug use and its effect on neonates: a population-based study in Washington State. Obstet Gynecol 2012;119:924–933.

e13.Katz DF, Sun J, Khatri V, et al. QTc Interval Screening in an Opioid Treatment Program. Am J Cardiol 2013.

e14.Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006;31:506–511.

e15.Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief 2009:1–8.

e16.CDC Web-based Injury Statistics Query and Reporting System (WISQARS)[online]. Available at Accessed April 17, 2013.

e17.Martin BC, Fan MY, Edlund MJ, Devries A, Braden JB, Sullivan MD. Long-term chronic opioid therapy discontinuation rates from the TROUP study. J Gen Intern Med 2011;26:1450–1457.

e18.Von Korff M, Saunders K, Thomas Ray G, et al. De facto long-term opioid therapy for noncancer pain. Clin J Pain 2008;24:521–527.

e19.White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999;94:961–972.

e20.Madadi P, Hildebrandt D, Lauwers AE, Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PLoS One 2013;8:e60600.

e21.Hall AJ, Loegan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008;300:2613–2620.

e22.Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States. July, 2010. [online]. Available at: Accessed January 1, 2014.

e23.ESHB 2876: An Act relating to pain management [Internet] [online]. Available at: Laws/House/2876-S.SL.pdf. Accessed December 30, 2013.

e24.Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113–130.

e25.Furlan AD, Reardon R, Weppler C. Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ 2010;182:923–930.

e26.Clinical Practice Guideline: Management of opioid therapy for chronic pain. VA/DOD evidence based practice. May, 2010. [online]. Available at: Accessed April 17, 2013.

e27.Opioid management of the injured patient. State of Connecticut Workers' Compensation Commission. [online]. Available at: Accessed April 17, 2013.

e28.An act to reduce opioid overprescription, overuse, and abuse. Maine laws Sec. 1. 22 MRSA c. 255-A [online]. Available at: Accessed April 17, 2013.

e29.New Mexico proposed rule 16.10.14: amendments on mandatory use of the state Prescription Drug Monitoring Program. [online]. Available at: Accessed April 17, 2013.

e30.State Medical Board of Ohio. Guidelines for Prescribing Opioids for the Treatment of Chronic, Non-Terminal Pain:

80 mg of a Morphine Equivalent Daily Dose (MED) “Trigger Point” [online]. Available at: Opioids Guidlines.pdf. Accessed November 25, 2013.

e31.Food and Drug Administration, August 2012: Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). [online]. Available at: Accessed April 17, 2013.

e32.Food and Drug Administration, July 2012. FDA blueprint for prescriber education for extended-release (ER) and long-acting (LA) opioid analgesics [online]. Available at: Accessed April 17, 2013.

e33.Statement on Proposed Hydrocodone Reclassification from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research [online]. Available at: Accessed February 11, 2014.

e34.US Food and Drug Administration. FDA announces safety labeling changes and postmarket study requirements for extended-release and long-acting opioid analgesics [online]. Available at: Accessed December 31, 2013.

e35.Electronic prescription for controlled substances. Federal Register, Vol 75, No 61, March 31, 2010, pp 16236-16319. 21 CFR Parts 1300, 1304, 1306, and 1311. [online]. Available at: Accessed April 17, 2013.

e36.The White House Office of National Drug Control Policy. Epidemic: Responding to America’s prescription drug abuse crisis. [online]. Available at: Accessed April 17, 2013.

e37.Franklin GM, Fulton-Kehoe D, Turner JA, Sullivan MD, Wickizer TM. Changes in opioid prescribing for chronic pain in Washington State. J Am Board Fam Med 2013;26:394–400.

e38.Southern Oregon Opioid Prescribing Guidelines [online]. Available at: Accessed May 8, 2014.